About This Calculator

The Gleevec (imatinib) Dose Calculator is a clinical support tool designed to determine appropriate starting doses based on patient type, specific indication, and organ function. It adheres to guidelines from the FDA-approved prescribing information to help healthcare professionals ensure dosing accuracy and safety, especially when accounting for pediatric body surface area (BSA) or adjustments for renal and hepatic impairment.

Outputs Explained

After processing the inputs, the calculator provides a clear, actionable dosing recommendation. The key outputs include:

• Recommended Dose: The final calculated dose in milligrams (mg), along with the dosing frequency (e.g., once daily or twice daily).
• Adjustment Rationale: A summary of any dose modifications made due to factors like severe hepatic or renal impairment.
• Administration Details: Practical guidance on how to administer the dose using available tablet strengths (e.g., 1 x 400 mg + 1 x 100 mg tablets) and a reminder to take the medication with a meal and a large glass of water.
• Key Parameters: For relevant calculations, it displays the calculated Body Surface Area (BSA) for pediatric patients or the Creatinine Clearance (CrCl) for renal function assessment.

How to Use the Tool

To ensure an accurate calculation, follow these steps:

1. Select Patient Type: Choose between “Adult” and “Pediatric” to load the appropriate indications and dosing formulas.
2. Choose Indication: Select the specific medical condition for which imatinib is being prescribed from the dropdown menu.
3. Specify Organ Function: Select the patient’s hepatic function status (Normal to Severe/Child-Pugh C). If renal dose adjustment is needed, check the box to reveal inputs for CrCl calculation.
4. Enter Patient Data: For pediatric patients, input height and weight to calculate BSA. For renal adjustments, either enter a known CrCl value or input the patient’s age, weight, serum creatinine, and gender for the tool to calculate it via the Cockcroft-Gault equation.
5. Review Results: The tool automatically calculates and displays the recommended dose and administration notes. No “calculate” button is needed; the results update in real-time.

Dosing Overview

Imatinib dosing varies significantly by indication and patient population. It should always be administered with a meal and a large glass of water to minimize gastrointestinal irritation.

• Adult CML (Chronic Phase): The standard starting dose is 400 mg once daily.
• Adult CML (Accelerated/Blast Crisis) & Ph+ ALL: The standard starting dose is 600 mg once daily.
• Pediatric CML & Ph+ ALL: The dose is calculated based on BSA at 340 mg/m²/day, not to exceed a maximum of 600 mg.
• Hepatic Impairment: For patients with severe hepatic impairment (Child-Pugh C), the starting dose should be reduced by 25%.
• Renal Impairment: For patients with severe renal impairment (CrCl < 20 mL/min), the starting dose should be reduced by 50%.

Switching Medications

Switching from another tyrosine kinase inhibitor (TKI) to imatinib, or from imatinib to another TKI, is a clinical decision that requires careful management by an oncologist or hematologist. The process involves considering the reason for the switch (e.g., resistance, intolerance), potential for cross-resistance, managing treatment-free intervals, and monitoring for adverse events. Do not switch treatments without direct medical supervision.

Missed Dose Protocol

If a dose of imatinib is missed, the patient should take the dose as soon as they remember. However, if it is almost time for the next scheduled dose, they should skip the missed dose and resume their regular dosing schedule. A double dose should never be taken to make up for a missed one.

Safety Alerts

Frequently Asked Questions

What BSA formula does the calculator use for pediatric dosing?

The calculator uses the Mosteller formula, which is standard in clinical practice: BSA (m²) = √([Height(cm) x Weight(kg)] / 3600).

How does the tool adjust the Gleevec dose for severe liver problems?

For patients with severe hepatic impairment (classified as Child-Pugh C), the calculator reduces the standard recommended starting dose by 25% as per the prescribing information.

What happens if I enter a CrCl of 35 mL/min?

For a CrCl between 20 and 59 mL/min (moderate renal impairment), the prescribing information advises caution but does not mandate a specific starting dose reduction. The calculator will note this but will not automatically reduce the dose. Dose tolerance should be closely monitored.

Does this calculator account for drug-drug interactions?

No. This tool calculates dose based on patient and organ function parameters only. Imatinib is a substrate of the CYP3A4 enzyme; co-administration with strong CYP3A4 inhibitors or inducers can significantly alter imatinib concentrations and may require dose adjustment. Always consult a pharmacist or drug database.

What is the maximum pediatric dose the calculator will recommend?

The maximum dose for pediatric indications (CML and Ph+ ALL) is capped at 600 mg per day, even if the BSA-based calculation results in a higher theoretical dose.

Why is the final calculated dose rounded?

Doses are rounded to the nearest 25 mg or 50 mg to allow for practical administration using the available 100 mg and 400 mg scored tablets.

Which formula is used for creatinine clearance (CrCl)?

The calculator uses the Cockcroft-Gault equation to estimate CrCl when patient parameters (age, weight, sex, serum creatinine) are provided.

Can I use this tool for unresectable or metastatic GIST?

Yes, the tool includes the standard 400 mg/day starting dose for unresectable and/or metastatic gastrointestinal stromal tumors (GIST).

References

1. GLEEVEC® (imatinib mesylate) Prescribing Information. U.S. Food and Drug Administration. Revised: Nov 2023.
2. Gleevec (imatinib mesylate) Healthcare Professional Information. Novartis Pharmaceuticals Corporation.
3. Imatinib Mesylate – National Cancer Institute. National Institutes of Health (NIH).